A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

NCT01450696 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

296

Enrollment

INDUSTRY

Sponsor class

Stopped futility following planned interim analysis

Conditions

Gastric Cancer

Interventions

DRUG: Capecitabine
DRUG: Cisplatin
DRUG: Herceptin

Sponsor

Hoffmann-La Roche